By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allele Biotech on Friday announced that it has signed a contract with the National Cancer Institute to conduct RNAi screening aimed at identifying synthetic targets for killing cancer cells.

The San Diego-based firm will use its high-quality fluorescent proteins, lentivirus systems, and shRNA platform for the project. It noted that the University of Florida is a sub-contractor on the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.